Theriva Biologics, Inc. (TOVX) Operating cash flow 2016–2025
Theriva Biologics, Inc. (TOVX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$16.7MFY2025 · since FY2016: -$27.9M → -$16.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$16.7M | +1.6% |
| FY2024 | -$16.9M | +10.8% |
| FY2023 | -$19.0M | +0.5% |
| FY2022 | -$19.1M | -48.0% |
| FY2021 | -$12.9M | -5.9% |
| FY2020 | -$12.2M | +12.3% |
| FY2019 | -$13.9M | +19.7% |
| FY2018 | -$17.3M | +14.5% |
| FY2017 | -$20.2M | +27.6% |
| FY2016 | -$27.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TOVX financial trends
TOVX RevenueTOVX Net incomeTOVX Net marginTOVX Gross profitTOVX Gross marginTOVX Operating incomeTOVX Operating marginTOVX Free cash flowTOVX Capital expendituresTOVX Return on equityTOVX Stock buybacksTOVX Dividends paidTOVX Total assetsTOVX Total liabilitiesTOVX Shareholders’ equityTOVX overview →